Investigation of novel design piezoelectric bending actuators

Two piezoelectric bending actuators of a novel design are presented and analysed in the paper. Numerical modelling and experimental study of the piezoelectric bending actuators were performed to verify operating principle and to investigate dynamic characteristics of the actuators. Numerical calculations are performed by using finite element method. Results of experimental study of piezoelectric actuators are compared with the results of finite element simulations. Results of the numerical and experimental research are analysed and discussed

Robust and Deterministic Preparation of Bosonic Logical States in a Trapped Ion

Encoding logical qubits in bosonic modes provides a potentially hardware-efficient implementation of fault-tolerant quantum information processing. Recent advancements in trapped ions and superconducting microwave cavities have led to experimental realizations of high-quality bosonic states and demonstrations of error-corrected logical qubits encoded in bosonic modes. However, current protocols for preparing bosonic code words lack robustness to common noise sources and can be experimentally challenging to implement, limiting the quality and breadth of codes that have been realized to date. Here, we combine concepts of error suppression via robust control with quantum error correction encoding and experimentally demonstrate high-fidelity, deterministic preparation of highly non-classical target bosonic states in the mechanical motion of a trapped ion. Our approach implements numerically optimized dynamical modulation of laser-driven spin-motion interactions to generate the target state in a single step. The optimized control pulses are tailored towards experimental constraints and are designed to be robust against the dominant source of error. Using these protocols, we demonstrate logical fidelities for the Gottesman-Kitaev-Preskill (GKP) state as high as $\bar{\mathcal{F}}=0.940(8)$, achieve the first realization of a distance-3 binomial logical state with an average fidelity of $\mathcal{F}=0.807(7)$, and demonstrate a 12.91(5) dB squeezed vacuum state.Comment: 12 pages, 8 figure

In silico evaluation of ultrafiltration and nanofiltration membrane cascades for continuous fractionation of protein hydrolysate from tuna processing byproduct

The present work proposes the design of cascades that integrate ultrafiltration (UF) and nanofiltration (NF) membranes to separate the different protein fractions from the protein hydrolysate obtained after hydrolysis of tuna byproducts. Experimental data (permeate flux and rejection of protein fractions under different applied pressures) previously obtained and published by this research group were fitted to empirical models, which were the basis for a process simulation model. High recovery rates (0.9) in the UF stages implied high process yields by reduced desired fraction losses, while similar recovery rates in the NF stages were required for high product purity. However, the applied pressures were not so influential over the performance of the system. Optimization problems were solved to identify the optimal design and operation conditions to maximize the product purity or the process yield. Maximal purity of the preferred 1-4 kDa fraction (49.3% from 19.0% in feed stream) obtained by the configuration with 3 UF stages and another 3 NF stages implied 2 and 5 bar pressures applied in the UF and NF stages, respectively, while 0.9 was the optimal recovery rate value for all the stages. These maximal purity conditions resulted in 62.6% process yield, defined as the percentage of the 1-4 kDa fraction in the feed stream recovered in the product stream. In addition, multiobjective optimization of the process was also carried out to obtain the Pareto graphs that represent the counterbalance between maximal yields and purities

Impacts of innovation, productivity and specialization on tourism competitiveness - a spatial econometric analysis on European regions

Tourism is clearly a place-based activity, while in many advanced economies it is increasingly becoming a knowledge-based activity, with a high potential for the development of practice- and place-based innovation strategies. This study analyses whether and how regional systems of innovation influence the competiveness of tourism destinations in Europe. Impacts of both traditional production factors (physical and human capital), productivity, specialization and other contextual variables - related to the territorial capital of each region - on regional tourism performance of 237 European regions (NUTS 2) are analysed over a period of 8 years, using advanced techniques for spatial econometric analysis. The results reveal lower levels of productivity in those regions where tourism services are more labour intensive, while regions where education, innovation and productivity demonstrate higher levels are those where gross value added in tourism is less important for the regional economy. Policy implications are discussed, taking into consideration the principles for smart specialisation strategies in European regions and the possibility for cross-border regional cooperation. This work also confirms the research potential of spatial econometric analysis - and in particular spatial autocorrelation techniques - for tourism studies.Fundacao para a Ciencia e a TecnologiaPortuguese Foundation for Science and TechnologyFEDER/COMPETEEuropean Union (EU) [UID/ECO/04007/2013, SFRH/BPD/98938/2013]info:eu-repo/semantics/publishedVersio

Application of the JA-CHRODIS Integrated Multimorbidity Care Model (IMCM) to a Case Study of Diabetes and Mental Health

The Integrated Multimorbidity Care Model (IMCM), developed by the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS), proposes a set of 16 multidimensional components (i.e., recommendations) to improve the care of persons with multimorbidity in Europe. This study aimed at analyzing the potential applicability of the IMCM. We followed a qualitative approach that comprised two phases: (1) The design of a case study based on empirical clinical data, which consisted of a hypothetical woman with multimorbidity, type 2 diabetes mellitus, mental health, and associated social problems, and (2) the creation of a consensus group to gather the opinions of a multidisciplinary group of experts and consider the potential applicability of the IMCM to our case study. Experts described how care should be delivered to this patient according to each model component, suggested the use of specific rating scales and tools to assess her needs in a comprehensive and regular way, and pointed our crucial health and social resources to improve her care process. Experts also highlighted patient-centered, integrated and tailored care as one of the keystones of quality healthcare. Our results suggest that the IMCM is applicable in complex patients with multimorbidity

A Methodological Approach for Implementing an Integrated Multimorbidity Care Model: Results from the Pre-Implementation Stage of Joint Action CHRODIS-PLUS

Patients with multimorbidity (defined as the co-occurrence of multiple chronic diseases) frequently experience fragmented care, which increases the risk of negative outcomes. A recently proposed Integrated Multimorbidity Care Model aims to overcome many issues related to fragmented care. In the context of Joint Action CHRODIS-PLUS, an implementation methodology was developed for the care model, which is being piloted in five sites. We aim to (1) explain the methodology used to implement the care model and (2) describe how the pilot sites have adapted and applied the proposed methodology. The model is being implemented in Spain (Andalusia and Aragon), Lithuania (Vilnius and Kaunas), and Italy (Rome). Local implementation working groups at each site adapted the model to local needs, goals, and resources using the same methodological steps: (1) Scope analysis; (2) situation analysis-"strengths, weaknesses, opportunities, threats" (SWOT) analysis; (3) development and improvement of implementation methodology; and (4) final development of an action plan. This common implementation strategy shows how care models can be adapted according to local and regional specificities. Analysis of the common key outcome indicators at the post-implementation phase will help to demonstrate the clinical effectiveness, as well as highlight any difficulties in adapting a common Integrated Multimorbidity Care Model in different countries and clinical settings

Integrating Entrepreneurship into the Design Classroom: Case Studies from the Developing World

© 2017, Springer Science+Business Media, LLC. Developing countries are more and more committed to building a knowledge-based economy as a means to diversify from their current resource-based economy. The current focus of many governments is on technology with real insights on creative economy and arts. In this context, universities are seen as a key partner of the government. This article presents the results of two innovative case studies of professors working in the College of Art and Design collaborating with a professor in the College of Business to integrate the concepts of entrepreneurship into their interior design courses. This was done through designing space for entrepreneurial projects and by the students acting as entrepreneurs themselves with an external client. This dual model of training combines (1) learning processes about the habits and the needs of entrepreneurs and (2) learning by acting as an entrepreneur. Such methods demonstrate the role of universities to provide a proper theoretical background for students and to foster entrepreneurial behaviors through arts entrepreneurship education. Furthermore, the central role of professors to introduce innovative teaching methods to combine entrepreneurship and the creative economy into non-business courses is an important finding in these case studies

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years